AI 用常规 CT 无创检测食管静脉曲张并预测肝癌患者肝功能失代偿
本研究为多中心回顾性研究,纳入 489 例接受阿替利珠单抗-贝伐珠单抗(AtezoBev)治疗的不可切除肝细胞癌(HCC)患者,利用动脉期增强 CT 的深度学习模型 HepatoSageCT 联合临床变量构建无创模型。结果显示,联合门体分流(PSS)与 HepatoSageCT 检测食管静脉曲张的 AUROC 达 0.84,决策算法漏诊需治疗静脉曲张仅 4.2%,且 HepatoSageCT 可预测肝功能失代偿(C-index 0.73)。
要点
- HepatoSageCT 联合 PSS 检测 EV 的 AUROC 为 0.84,漏诊需治疗静脉曲张 4.2%。
- HepatoSageCT 预测肝功能失代偿的 C-index 为 0.73,风险比 3.17。
- 高风险分层患者总生存期显著更短(p <0.001)。
核心结论
- HepatoSageCT 评分联合临床数据可无创准确检测 AtezoBev 治疗的不可切除 HCC 患者的 EV。
- 该模型能对肝功能失代偿风险进行分层,可能减少不必要的内镜检查并改善预后评估。
研究设计与样本
- 多中心回顾性研究,纳入 489 例接受 AtezoBev 治疗的不可切除 HCC 患者,来自法国五个中心。
- 分为开发队列(n = 279)和外部验证队列(n = 210)。
- 动脉期增强 CT 经深度学习流程处理,使用基础模型 HepatoSageCT,构建 logistic 和 Cox 模型。
主要发现
- 影像学门体分流(PSS)检测 EV 的 AUROC 为 0.78,联合 HepatoSageCT 后升至 0.84。
- 决策算法联合 PSS 和 HepatoSageCT 漏诊需治疗静脉曲张 4.2%,仅用 PSS 漏诊 8.4%,大 EV 漏诊 0%。
- HepatoSageCT 在验证队列预测肝功能失代偿的 C-index 为 0.73,风险比 3.17,分层显著(p <0.001)。
- 联合腹水、脾大和 HepatoSageCT 风险的复合评分 C-index 为 0.73,风险比 3.48。
- HepatoSageCT 分层高风险患者总生存期显著更低(p <0.001)。
关键数值与推荐
- PSS 检测 EV 的 AUROC 为 0.78,联合 HepatoSageCT 为 0.84。
- 决策算法漏诊需治疗静脉曲张 4.2%(联合) vs 8.4%(仅 PSS),大 EV 漏诊 0%。
- HepatoSageCT 预测失代偿验证队列 C-index 0.73,HR 3.17,p <0.001。
- 复合评分 C-index 0.73,HR 3.48。
临床怎么用
- 可利用常规增强 CT 和临床数据(如 PSS)无创评估 EV 和肝功能失代偿风险。
- 该工具可能减少不必要的内镜筛查,支持及时风险分层和个体化管理。
- 仍需前瞻性验证后方可用于临床决策。
局限性
- 回顾性研究设计。
- 需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In hepatocellular carcinoma (HCC) with cirrhosis, portal hypertension worsens outcomes. Esophagogastroduodenoscopy (EGD), the current screening method for esophageal varices (EVs), is invasive and may delay therapy. We aimed to develop and externally validate non-invasive models to detect EVs and predict hepatic decompensation (bleeding, ascites or hepatic encephalopathy), a major cause of mortality in patients with HCC, using routine contrast-enhanced CT and clinical data. METHODS: This multicenter retrospective study included 489 patients with unresectable HCC treated with atezolizumab-bevacizumab (AtezoBev) from five French centers, divided into a development cohort (n = 279) and an external validation cohort (n = 210). Arterial-phase contrast-enhanced CTs were processed through a Deep Learning pipeline using a foundation model (HepatoSageCT). Logistic and Cox models generated clinical models and combined models integrating the HepatoSageCT scores with key clinical variables for EVs and hepatic decompensation. Performance was assessed using AUROC, sensitivity, specificity, C-index and cause-specific hazard ratios. RESULTS: Portosystemic shunts (PSS) at imaging identified EVs with an AUROC of 0.78, increasing to 0.84 when combined with HepatoSageCT. A decision algorithm incorporating PSS and HepatoSageCT missed 4.2% of varices needing treatment, compared to 8.4% when using only PSS, while missing 0% of large EVs. HepatoSageCT predicted hepatic decompensation in the validation cohort (C-index: 0.73, hazard ratio: 3.17) with significant stratification (p <0.001), comparable to a composite score of ascites, splenomegaly and HepatoSageCT risk (C-index: 0.73, hazard ratio: 3.48). Patients stratified at higher risk of decompensation by HepatoSageCT also exhibited significantly lower overall survival (p <0.001). CONCLUSIONS: HepatoSageCT scores, supplemented with clinical data, enable accurate non-invasive detection of EV in AtezoBev-treated unresectable HCC and stratify patients according to their risk of hepatic decompensation. This approach may reduce unnecessary endoscopies and improve prognostic assessment. IMPACT AND IMPLICATIONS: The present study demonstrates that foundation models applied to routine CT imaging, when combined with routinely collected features such as the presence of portosystemic shunts, can accurately predict the presence of esophageal varices and the risk of first or further hepatic decompensation in patients with AtezoBev-treated unresectable hepatocellular carcinoma. These findings are particularly relevant for hepatologists and oncologists, as they highlight a promising non-invasive tool for timely risk assessment in a time-sensitive patient population. While prospective validation is warranted, this approach could support more personalized management and care of patients with unresectable hepatocellular carcinoma.
引用
- Rabasco Meneghetti A, Campani C, Roux C, et al. Detection of esophageal varices and prediction of hepatic decompensation in unresectable hepatocellular carcinoma using AI. J Hepatol. 2026. PMID: 41679555. doi:10.1016/j.jhep.2026.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。